A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells.

ABSTRACT: Resistance to chemotherapy remains a major obstacle for the treatment of breast cancer. Understanding the molecular mechanism(s) of resistance is crucial for the development of new effective therapies to treat this disease. This study examines the putative role of p130(Cas) (Cas) in resistance to the cytotoxic agent Adriamycin. High expression of Cas in primary breast tumors is associated with the failure to respond to the antiestrogen tamoxifen and poor prognosis, highlighting the potential clinical importance of this molecule. Here, we show a novel association between Cas and resistance to Adriamycin. We show that Cas overexpression renders MCF-7 breast cancer cells less sensitive to the growth inhibitory and proapoptotic effects of Adriamycin. The catalytic activity of the nonreceptor t

SUBMITTER: Ta HQ 

PROVIDER: S-EPMC2597570 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature